• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NextPlat Issues Interim CEO Update Shareholder Letter

    6/30/25 8:01:00 AM ET
    $NXPL
    $OPK
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXPL alert in real time by email

    COCONUT GROVE, Fla., June 30, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter:

    NextPlat Corp. logo (PRNewsfoto/NextPlat Corp.)

    To Our Shareholders:

    As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward.

    In the month since the unexpected passing of our former CEO and Chairman, Charles M. Fernandez, our team has been closely reviewing our operations to build on the strong foundation he helped create. As part of this, I personally met with leaders across our subsidiaries and was truly impressed by the passion and dedication of our highly experienced employees. Based on the insights I gathered, I'm confident that with greater focus, improved coordination, and targeted investment, NextPlat is well-positioned to capitalize on the opportunities ahead and unlock significant value.

    Where We Are Today

    Having completed my initial review, I believe that our healthcare division is particularly critical to our future success as it currently represents the largest part of our business and offers significant untapped opportunities to explore. I believe there are several areas that we need to address if we are to properly support the business and reach our long-term goals, foremost amongst them being:

    • Continued operational process efficiency and cost reduction efforts to drive maximum ROI
    • Ensuring that we have the necessary talent leading our units and that they are empowered to manage and drive growth
    • Renewing a commitment to prudently invest in the business to help capitalize on growth opportunities, both organic and non-organic, while enhancing cashflow and long-term profitability

    Where We Are Going – Pharmacy and Healthcare

    As we've previously communicated, the retail pharmacy sector continues to face unprecedented challenges driven by rising drug costs and made worse by reimbursement rates not keeping pace with those rising costs. Therefore, our focus must remain on executing the business of the Company efficiently and investing in alternative areas of healthcare that offer growth potential.

    To that end, we've been working to streamline our current healthcare operations and expand our contracted 340B and long-term care (LTC) services, both of which present opportunities for profitable growth. We also intend to take several strategic steps within our healthcare business, including:

    • Adding experienced healthcare leadership to the team to drive growth and enhance the daily management and profitability of the business
    • Expanding into new, high growth/high margin healthcare services through joint ventures and partnerships
    • Implementing a number of process and technology improvements designed to drive additional operational efficiencies, improve compliance, and attract a new customer demographic
    • Make further investments into marketing and sales programs targeting 340B and LTC providers, including the exploration of obtaining licenses in nearby southeastern states where additional 340B opportunities exist
    • Adding complementary services such as compounding, additional OTC products, and exploring opportunities such as opening in-house pharmacies
    • Pursuing special accreditation to enable us to dispense specialty medications, potentially leading to broader patient access and increased prescription volume on high margin sales
    • Begin targeting the non-insured (cash) sales market to diversify revenue streams and reduce dependence on insurance reimbursements
    • Evaluate opportunities for nationwide licensing to enable e-Commerce mail-order sales
    • Improving customer service responsiveness, access and support

    Where We Are Going - E-Commerce

    Although e-Commerce represents a smaller part of NextPlat's overall business, I have spoken in the past about the vast global opportunity and potential we see in this business. Through leading e-Commerce marketplaces such as Amazon.com, Walmart, and Alibaba in China, as well as our own network of branded online storefronts, we have created a global presence supporting tens of thousands of customers in over 150 countries. This is something we intend to build on.

    Recently, new tariffs, particularly between the U.S. and China, have delayed product launches like our Florida Sunshine vitamin brand, but we still see strong global opportunities ahead. That is why we are focusing on growing our e-Commerce business through a series of initiatives including:

    • Further scaling our global e-Commerce presence through small, opportunistic acquisitions that bring accretive sales, distribution and potentially, valuable contracts and customer lists
    • Launching new international marketplaces, forming new distribution partnerships, and introducing new products and services to further expand our global customer base
    • Advance our recently launched storefront design and product management service for hardware manufacturers and connectivity services providers, helping them to build, optimize, and grow their brands in the world's largest online marketplaces and reach new customers.
    • Expanding our e-Commerce partnership with OPKO Health, Inc. (NASDAQ:OPK) ("OPKO") for sales into China of its health, nutrition, and dietary supplement products, adding unique animal care products later this year, all of which are not subject to any current tariffs
    • Continuing to explore opportunities to launch our Florida Sunshine vitamin brand in the UK and EU, following a setback of this project as a result of Chinese tariffs.

    For Our Shareholders

    As I indicated earlier in this update, the team at NextPlat shares a common belief in the long-term opportunities ahead of us and the ability to build upon the strong foundation created under Charlie's leadership. Our internal business review identified our strengths as well as areas that need immediate attention and improvement if we are to meet our growth and profitability objectives. That is why we are committed to addressing several areas and needs in the business, including:

    • Accelerating ongoing efforts to maximize efficiencies across the organization with the bottom-line goal of generating positive operating results and ROI
    • Investing in our operations and our people to profitably expand and grow the business
    • Fill gaps in our team and empower our leaders to execute against their respective growth plans
    • Implement the stock buyback program previously announced
    • Continue to improve shareholder transparency and engagement including outreach to the broader investor community

    A Thank You

    In conclusion, we must thank our partners, customers, employees, and investors for their continued support and wish to confirm our pledge that we intend to use recent developments as a catalyst for change and as an opportunity to advance Charlie's legacy. Although we have challenges ahead, Charlie created a strong and well-funded foundation for us to build on, and both I and our Board are committed to realizing and surpassing the potential he saw for NextPlat in the months and years ahead.

    Sincerely,

    David Phipps

    Interim Chief Executive Officer

    About NextPlat Corp

    Nextplat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

    Forward-Looking Statements

    Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

    Media and Investor Contact for NextPlat Corp:

    Michael Glickman

    MWGCO, Inc.

    917-397-2272

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-issues-interim-ceo-update-shareholder-letter-302494111.html

    SOURCE NextPlat Corp.

    Get the next $NXPL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXPL
    $OPK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $NXPL
    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    4/25/25 8:32:28 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health upgraded by Barrington Research with a new price target

    Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00

    6/29/23 9:11:26 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Opko Health with a new price target

    H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00

    12/15/22 8:08:28 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    SEC Filings

    View All

    NextPlat Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NextPlat Corp (0001058307) (Filer)

    8/14/25 2:46:37 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    SEC Form 10-Q filed by OPKO Health Inc.

    10-Q - OPKO HEALTH, INC. (0000944809) (Filer)

    7/31/25 4:12:38 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OPKO HEALTH, INC. (0000944809) (Filer)

    7/31/25 4:07:20 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NextPlat Reports Second Quarter 2025 Results

    Company Reports $13.2M in Q2 Revenue, Achieves Significant Reduction in Operating Expenses and Continues Cost Reduction and Efficiency Improvements to Support Growth COCONUT GROVE, Fla., Aug. 14, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced the financial results for the quarter-ended June 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations. "R

    8/14/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat to Release Second Quarter 2025 Results on Thursday, August 14, 2025

    Investor Conference Call Scheduled for Thursday, August 14, 2025 at 8:30 a.m. Eastern COCONUT GROVE, Fla., Aug. 6, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced that it will release its financial results for the quarter ended June 30, 2025 before market open on August 14, 2025. NextPlat's Interim CEO, President and CEO of Global Operations, David Phipps and its Chief Finan

    8/6/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 healthy adults. Based on analysis of these results, Merck will determine whether and how to proceed with Phase 2 studies.ModeX continued to advance its immuno-oncology and immunology portfolio with four potential clinical candidates

    7/31/25 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $891,000 worth of shares (675,000 units at $1.32) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    8/8/25 4:56:12 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $169,712 worth of shares (125,000 units at $1.36) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    4/10/25 5:07:15 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $184,650 worth of shares (125,000 units at $1.48) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    4/8/25 5:34:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Financials

    Live finance-specific insights

    View All

    NextPlat Reports Second Quarter 2025 Results

    Company Reports $13.2M in Q2 Revenue, Achieves Significant Reduction in Operating Expenses and Continues Cost Reduction and Efficiency Improvements to Support Growth COCONUT GROVE, Fla., Aug. 14, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced the financial results for the quarter-ended June 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations. "R

    8/14/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat to Release Second Quarter 2025 Results on Thursday, August 14, 2025

    Investor Conference Call Scheduled for Thursday, August 14, 2025 at 8:30 a.m. Eastern COCONUT GROVE, Fla., Aug. 6, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced that it will release its financial results for the quarter ended June 30, 2025 before market open on August 14, 2025. NextPlat's Interim CEO, President and CEO of Global Operations, David Phipps and its Chief Finan

    8/6/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 healthy adults. Based on analysis of these results, Merck will determine whether and how to proceed with Phase 2 studies.ModeX continued to advance its immuno-oncology and immunology portfolio with four potential clinical candidates

    7/31/25 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $891,000 worth of shares (675,000 units at $1.32) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    8/8/25 4:56:12 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO & Chairman Frost Phillip Md Et Al

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    5/29/25 5:08:32 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Vice Chairman & CTO Hsiao Jane Ph D

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    5/29/25 5:07:08 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Leadership Updates

    Live Leadership Updates

    View All

    $NXPL
    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextPlat Announces Results of Annual Meeting of Stockholders

    Business Combination with Progressive Care Inc. Approved with Anticipated Closing Date of October 1, 2024 COCONUT GROVE, Fla., Sept. 16, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW))) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced the results of the Company's Special Annual Meeting of Stockholders ("the Annual Meeting") held on September 13, 2024. At the Annual Meeting, shareholders were asked to vote on six proposals, the most notable being the following: A proposal to approve and adopt the Merger Agreement and Plan of Reorganization p

    9/16/24 5:35:00 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

    NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

    9/15/22 4:05:00 PM ET
    $OPK
    $TALK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care